Psoriasis Clinical Trial
A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis
Summary
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
Eligibility Criteria
Inclusion Criteria:
Male or female, aged 18 to 75 years (inclusive)
Have a diagnosis of plaque type psoriasis for ≥ 6 months
Must have chronic plaque type psoriasis of moderate severity
All subjects must agree and commit to the use of a reliable contraceptive regimen.
Exclusion Criteria:
Current diagnosis of forms of psoriasis other than chronic plaque type only
Drug-induced psoriasis
Other inflammatory skin disease that may confound the evaluation of plaque psoriasis
Failed 2 or more systemic treatments for plaque psoriasis
Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to Baseline Visit
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Birmingham Alabama, 35205, United States
Santa Ana California, 92701, United States
Santa Monica California, 90404, United States
Doral Florida, 33122, United States
Hialeah Florida, 33012, United States
Baton Rouge Louisiana, 70809, United States
Kogarah New South Wales, 2217, Australia
Westmead New South Wales, 2145, Australia
Woolloongabba Queensland, 4102, Australia
East Melbourne Victoria, 3002, Australia
How clear is this clinincal trial information?